Microba Life Sciences Limited (ASX:MAP)

Market Cap	24.51M -50.9%
Revenue (ttm)	14.76M -5.8%
Net Income	-20.72M
EPS	-0.03
Shares Out	700.31M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	46,361
Open	0.0350
Previous Close	0.0350
Day's Range	0.0350 - 0.0350
52-Week Range	0.0330 - 0.1050
Beta	2.10
Analysts	n/a
Price Target	n/a
Earnings Date	Oct 27, 2026

About Microba Life Sciences

Microba Life Sciences Limited provides microbiome testing, supplements, and analysis services in Australia, Europe, New Zealand, the United Arab Emirates, the United Kingdom, the United States, Asia, and Ireland. It operates through, Testing Services and Supplements, and Research and Development segments. The company also develops pathology, therapeutics, and diagnostics services based on the human gut microbiome. In addition, it offers MetaPanel, a metagenomic test for pathogen detection; microba microbiome explorer; research testing services;...

• Industry: Diagnostics & Research
• Sector: Healthcare
• Founded: 2017
• Country: Australia
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: MAP

Financial Performance

In fiscal year 2026, Microba Life Sciences's revenue was 14.76 million, a decrease of -5.81% compared to the previous year's 15.67 million. Losses were -20.72 million, 38.7% more than in 2025.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Oct 28, 2026

Data Sources Report a data error